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Abstract 
Background: Many HIV infected individuals with suppressed viral loads experience chronic immune activation fre-
quently developing neurological impairment designated as HIV associated neurocognitive disorder (HAND). Adjunc-
tive therapies may reduce HIV associated inflammation and therefore decrease the occurrence of HAND.
Methods: We have conducted in vitro, animal and clinical studies of the neurokinin 1 receptor (NK1R) antagonist 
aprepitant in HIV/SIV infection.
Results: Aprepitant inhibits HIV infection of human macrophages ex vivo with an ED50 ~ 5 µM. When administered 
at 125 mg once daily for 12 months to SIV-infected rhesus macaques, aprepitant reduced viral load by approximately 
tenfold and produced anti-anxiolytic effects. The anti-viral and anti-anxiolytic effects occur at approximately the third 
month of dosing; and the effects are sustained throughout the duration of drug administration. Protein binding 
experiments in culture media and animal and human plasma indicate that the free fraction of aprepitant is lower than 
previously reported supporting usage of higher doses in vivo. The analysis of blood samples from HIV positive indi-
viduals treated for 2 weeks with aprepitant at doses up to 375 mg demonstrated reduced levels of pro-inflammatory 
cytokines including G-CSF, IL-6, IL-8 and TNFα. Decreased pro-inflammatory cytokines may reduce HIV comorbidities 
associated with chronic inflammation.
Conclusions: Our results provide evidence for a unique combination of antiretroviral, anti-inflammatory and 
behavioral modulation properties of aprepitant in vitro and in vivo. These results provide robust support for a clinical 
exposure target above that recommended for chemotherapy-induced nausea and vomiting. Doses up to 375 mg 
once daily in HIV-infected patients still elicit sub-therapeutic exposure of aprepitant though effective plasma concen-
trations can be achievable by proper dose modulation.
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Background
Advances in combined antiretroviral therapy (cART) [1] 
have made considerable improvements in morbidity and 
mortality for HIV infected individuals turning HIV into a 
chronic disease with a growing numbers of people living 
with infection. HIV-infected individuals however con-
tinue to have a shorter life expectancy and a higher risk 
of cardiovascular events, liver and kidney diseases, meta-
bolic disorders, bone disease, and now have malignan-
cies compared to the earlier days of the AIDS epidemic. 
HIV-infected individuals often experience increased 
immune activation, inflammation and coagulation what 
is now recognized as key features of pathogenesis of 
chronic HIV infection even with viral loads suppressed 
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individuals will develop (HAND) despite treatment with 
cART [1]. HIV causes nervous system disease at all stages 
of infection with adverse effects on quality of life, adher-
ence to medications, employment and survival. HAND is 
often undiagnosed and untreated in both adolescents and 
adults. Issues that confound the presentation and treat-
ment of HIV-induced nervous system disorders include 
the increasing prevalence of drug-resistant HIV strains, 
increasing age of HIV-infected patients, and hepatitis 
C virus co-infection. The clinical presentation, underly-
ing the pathogenesis and treatment of this expanding 
group of neurocognitive and neurobehavioral disorders 
represent the clinical spectrum for which agents to treat 
HAND are needed.
Multiple adjuvant therapies with various mechanisms 
of action have been studied in HIV associated neuro-
cognitive disorder (HAND), but none so far have shown 
a clear positive effect [4]. Current research targets sub-
stance P (SP) and its preferring receptor NK1R signal-
ing pathway which mediates the interaction between the 
immune system and the nervous system [5, 6]. Aprepi-
tant, an antiemetic substance P antagonist is approved for 
prevention of chemotherapy induced nausea and vomit-
ing (CINV) has features which also make it an attractive 
candidate to treat residual inflammation in chronic HIV 
infection [5, 6]. Aprepitant crosses the blood–brain bar-
rier [7], has immune-stimulatory and anti-inflammatory 
properties [5, 6, 8, 9] and some studies suggest that it 
improves general well-being and reduce depression [10] 
though this is not universally accepted. Extensive data 
support the premise that SP–NK1R signaling is impor-
tant in the pathogenesis of HIV [6, 11–13]. HIV-infected 
men and women have elevated plasma levels of SP [14, 
15]. The addition of SP in  vitro enhances HIV replica-
tion in blood-isolated monocyte derived macrophages 
(MDM) and T-cells and NK1R antagonists inhibit this 
effect [12, 16–20].
The clinical datum supporting aprepitant’s clinical 
utility is defined by an acutely-treated CINV indication 
[21] and a poorly defined therapeutic window in patients 
with depression [22]; data in HIV-infected patients 
generated thus far have been based on pilot investiga-
tions of subtherapeutic doses at an insufficient duration 
of therapy to detect a meaningful clinical response [23, 
24]. Our overall objectives for this investigation were to 
examine the exposure targets from in vitro, ex vivo and 
in  vivo pharmacology studies with the goal of defining 
the dose–response relationship which support immune-
stimulatory and anti-inflammatory benefit across experi-
ment type, mechanism of action and organ system and 
species studied. Specifically, protein binding experi-
ments conducted in culture media used for infectivity 
experiments and in the monkey (SIV animal model) and 
human plasma to confirm/revise the dose requirements 
based on accurate determination of the target free frac-
tion. Ex  vivo samples from donor subjects treated with 
aprepitant were used to determine pro-inflammatory 
cytokine response and establish a preliminary concen-
tration-effect relationship. Samples from depressed and 
non-depressed HIV-negative patients were assessed for 
concentration-effect relationship of HIV infection of 
human macrophages treated with aprepitant. An in vivo 
pharmacology study in chronically treated SIV-infected 
rhesus macaques was conducted to assess anti-viral and 
behavioral responses. These results were collectively ana-
lyzed to determine their projection of clinically meaning-
ful exposures in patients with HAND by conventional 
and model-based extrapolation techniques.
Methods
HIV infection and depression: patients utilized for ex vivo 
analysis
The effect of aprepitant on HIV infection was assessed 
ex  vivo using monocyte-derived macrophages (MDM) 
from subjects recruited in conjunction with the clinical 
study “Depression Antidepressants and HIV infectiv-
ity” supported by R01-MH082670 [25]. A total of 150 
depressed and non-depressed HIV negative participants 
completed structured diagnostic psychiatric assess-
ments (SCID) for the presence of depression, Hamilton 
depression rating (17-item scale) and medical evalua-
tion. Monocytes from 125 individuals of this cohort were 
available for the current investigation. Of this sample 
population, 70 (56 %) were female, 78 (62 %) were Afri-
can American and 79 (63 %) were depressed. Ages ranged 
from 18 to 58  years (median 32  years). Subjects were 
excluded for medical comorbidities, current substance 
addiction, or use of psychotropic or immunomodulatory 
drugs in the 4 weeks prior to assessment. Blood samples 
were collected from the antecubital vein and monocytes 
were isolated as described below. The study was spon-
sored by the National Institutes of Mental Health and 
approved by the IRB of the University of Pennsylvania.
The effect of aprepitant treatment on cytokine pro-
duction in  vivo was studied using blood samples from 
patients enrolled in two separate randomized, placebo-
controlled, double-blind phase IB trials evaluating the 
safety and antiviral activity of aprepitant. Details of these 
studies have been previously described [23, 24]. The 
study was conducted at AIDS Clinical Trials Unit and the 
Clinical and Translational Research Center (CTRC) of 
the Hospital of the University of Pennsylvania in Phila-
delphia, PA, USA. All patients signed a written informed 
consent. The study was sponsored by the National 
Institutes of Mental Health, approved by the IRB of 
the University of Pennsylvania, the US Food and Drug 
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Administration (IND#75,558) and registered in Clinical 
Trials.gov (NCT00428519 and NCT01300988).
Cell isolation and aprepitant effect on cytokine production 
PD‑1 expression and HIV infection ex vivo
For HIV infectivity experiments PBMC were isolated from 
freshly collected blood samples using Ficoll-Paque (GE 
Healthcare, Uppsala, Sweden) gradient. Monocytes were 
purified by adhesion as described [26, 27] and cultured 
in 48-well plates at a density of 0.25 × 106/0.5 ml/well in 
DMEM supplemented with 10  % FBS for 7  days before 
HIV-1 infection. Macrophages from each subject were 
exposed to four experimental conditions (none, 1, 5 and 
10  µM of aprepitant). 7-day-cultured MDM were incu-
bated with aprepitant for 2 h before infection with HIV-1 
Bal (NIH AIDS Reagent Program), 5 ng/well based on p24 
antigen assay, corresponding to a MOI of 0.02 determined 
using MAGI cells expressing CD4 and CCR5 (NIH AIDS 
Reagent Program). Cells were incubated with virus over-
night, and then extensively washed to remove unbound 
virus. The culture medium and the aprepitant were 
replaced twice weekly. At day 7 post HIV infection, cellular 
RNA was extracted from the MDM for assessment of HIV 
gag mRNA expression using real time RT-PCR assays.
For cytokine and PD-1 assessment experiments freshly 
isolated peripheral blood mononuclear cell (PBMC) 
purchased from the Human Immunology Core Facility 
of The University of Pennsylvania School of Medicine 
(Philadelphia, PA) were cultured in RPMI medium sup-
plemented with 10 % FBS overnight. Some cultures were 
treated with SP (10  µM) aprepitant (10  µM) or DMSO 
(0.001  %, vehicle for aprepitant). Cytokine concentra-
tions were measured in supernatants using multiplex 
assay 24 h after SP/aprepitant treatment (see below). For 
PD-1 expression SP and aprepitant were added at day 0 
and PD-1 expression was monitored daily for up to 8 days 
using flow cytometry.
RNA extraction and real‑time RT PCR assays
Total RNA was extracted from MDM cells using RNeasy 
kit (Qiagen), and the potential DNA contamination was 
eliminated by on-column DNase digestion as instructed 
by the manufacturer (Qiagen). Total RNA (1  µg) was 
reverse transcribed using AffinityScript QPCR cDNA 
Synthesis kit (STRATAGENE, Cedar Creek, TX) with 
random primer as instructed by the manufacture. 1  µl of 
the resulting cDNA was used as a template for real-time 
PCR amplification. Primers and probes for real-time PCR 
were synthesized by Integrated DNA Technologies, Inc. 
(Coralville, IA) as following: intracellular HIV RNA was 
detected using primers to the gag region as described 
[28] sense-5′-CATGTTTTCAGCATTATCAGAAGGA, 
a n t i s e n s e - 5 ′ - T G C T T G AT G T C C C C C C A C T, 
probe- 5′-FAM-CCACCCCACAAGATTTAAACAC 
CATGCTAA-Q. Levels of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) were used for normalization: 
sense-5′-GTGGTCTCCTCTGACTTCAACA, antisense-
5′-TGCTGTAGCCAAATTCGTTG, probe 5′-5′-FAM-
CTGGCATTGCCCTCAACGACC-Q. PCR was performed 
using iQ iCycler system (Bio-Rad Laboratories, Inc., Hercu-
les, CA). Corresponding fragments of assayed genes cloned 
in pGEM-T vector (Promega) were used to generate stand-
ard curves.
Multiplex cytokine assay
Concentrations of pro-inflammatory cytokines and 
chemokines in supernatants of human PBMC were 
measured using human Cytokine/Chemokine Magnetic 
Bead Panel—Premixed 30 Plex, HCYTMAG-60K-PX30 
(Millipore, Billerica, MA, USA) as recommended by the 
manufacturers.
Soluble CD163 (sCD163) assay
sCD163 was measured by ELISA (Trillium Diagnos-
tics, Brewer, Maine, USA) according to manufacturer’s 
recommendations.
Non‑human primates
All experiments involving non-human primates were 
conducted at the Tulane National Primate Research 
Center. All experiments were approved by the Tulane 
Institutional Animal Care and Use Committee (Proto-
col 3267-B00). The Tulane National Primate Research 
Center (TNPRC) is an Association for Assessment and 
Accreditation of Laboratory Animal Care International 
accredited facility (AAALAC #000594). The NIH Office 
of Laboratory Animal Welfare assurance number for the 
TNPRC is A3071-01. All clinical procedures, including 
administration of anesthesia and analgesics, were carried 
out under the direction of a laboratory animal veterinar-
ian. Animals were anesthetized with ketamine hydro-
chloride for blood collection procedures. All possible 
measures are taken to minimize discomfort of all the ani-
mals used in this study. Tulane University complies with 
NIH policy on animal welfare, the Animal Welfare Act, 
and all other applicable federal, state and local laws. All 
animals were from the Specific Pathogen Free breeding 
colony at the TNPRC. All animals were pair-housed in 
one room. Pairs were housing in interconnected caged 
depending on body weight of individual animals. The 
room was maintained on a 12:12 h light:dark cycle. The 
ambient temperature remained between 64 and 72  °F. 
Subjects were fed commercial biscuits twice daily and 
had access to fresh, clean water ad libitum.
A pilot study in two groups of three male Rhesus 
macaques (Macaca mulatta) was conducted to assess the 
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exposure attained following once daily dosing of 80 and 
125 mg aprepitant administered orally for 14 days (n = 3 
per dose group). The 80 and 125  mg doses correlate 
with the human doses recommended for CINV patients 
(125 mg orally 1 h prior to chemotherapy treatment (day 
1) and 80 mg orally once daily in the morning on days 2 
and 3). On a weight basis these doses represent approxi-
mately 8 and 12.5 mg/kg (weight range, 7–12 kg for the 
rhesus) compared to 1.14 and 1.79  mg/kg human doses 
(assuming a 70 kg man). Higher weight-based doses were 
chosen based on the results of infectivity experiments 
supporting in  vivo exposure targets an order of magni-
tude higher than observed with current CINV dosing 
regimens. Blood was collected for dense PK sampling on 
days 1, 7 and 14 and trough samples were collected prior 
to dosing on days 3, 5, 7, 11 and 13.
For infectivity studies, eight male rhesus macaques 
were used. Animals were infected intravenously with 
50 ng p27 of SIV. Following infection four animals were 
treated with aprepitant once daily dosing of 125  mg 
aprepitant administered orally for a year and four infected 
animals were left untreated. Aprepitant (commercial cap-
sule contents) was mixed and co-administered with vari-
ous food preparations to ensure dosing compliance. Food 
preparations included peanut butter, marshmallow cream 
and honey, disguised in non-citrus fruit. While formal 
stability and delivery experiments were not conducted, 
pilot bioavailability studies confirmed the robustness of 
aprepitant exposures following food co-administration. 
The improved bioavailability with food-based dosing in 
conjunction with oral aprepitant is consistent with pre-
clinical experiments which project simulated exposures 
based on the commercial nanosized aprepitant formula-
tion. In this evaluation, in silico model predictions were 
similar to observed in vivo pharmacokinetic data in the 
fed state [29]; other studies have shown the benefit of 
complexation strategies to enhance aprepitant solubility/
dissolution [30, 31].
Blood was collected for PK sampling on days 1, 7 and 
14 and trough samples were collected prior to dosing on 
days 3, 5, 7, 11 and 13. Viral loads were assessed at 2 and 
4 weeks after infection and monthly thereafter. One sub-
ject in the SIV-infected control group was excluded from 
the analysis due to its atypical response to SIV inocula-
tion. Behavioral data were collected using video cameras 
installed on walls opposite the caging. Videotaping was 
scheduled to avoid disruptions in daily feedings, routine 
husbandry and research procedures. Data were collected 
pre-infection, 2 and 4 weeks post-infection and monthly 
thereafter. Videotaped recordings were analyzed using 
Observer XT® (Noldus IT). Animals were sacrificed and 
necropsied after 1 year.
Bioanalysis and pharmacokinetics
A validated, liquid chromatography-tandem mass spec-
trometry method was used for the quantification of 
aprepitant plasma concentration in HIV infected ani-
mals and tissue culture media. The method utilized a 
simple sample-preparation procedure of protein pre-
cipitation with methanol. Chromatographic separation 
was performed on a reversed phase C8 column (Hyper-
sil Gold, 50 mm × 2.1 mm, 3 μm) using a mobile phase 
composed of acetonitrile and water in 0.5 % formic acid 
through gradient elution. Electro-spray ionization in pos-
itive mode was incorporated in the tandem mass spec-
trometric detection. The lower limit of quantitation of 
aprepitant in human plasma was 1 ng/mL. Details of the 
method validation have been previously published [32].
Protein binding study
Protein binding experiments in human plasma and vari-
ous experimental media were used to assess in  vitro 
potency of aprepitant in 10 % FBS solution. These experi-
ments were conducted to assess the linkage between 
in  vitro and in  vivo exposure targets in order to more 
accurately project clinical dose requirements for aprepi-
tant. Protein binding was assessed via ultrafiltration and 
detection of aprepitant in various biofluids was con-
ducted via LC–MS/MS.
Ultrafiltration units (CorningR Spin-X UF; MWCO 
10  K) and filtrate collection tubes were obtained from 
Corning (Tewksbury, MA). Control human plasma 
was obtained by centrifugation of blood obtained from 
CHOP blood bank. Stock solutions of aprepitant in 
methanol were added to human plasma (1 %, v/v) to pro-
vide plasma samples at a nominal concentration of 10 μg/
mL. This was further diluted with human plasma to pro-
vide 5, 2 and 0.5 μg/mL solutions. Similarly, aprepitant at 
above four concentration were also prepared in 10 % FBS 
in DMEM or 10 % FBS in water. Samples were incubated 
at 37 °C for 30 min to ensure equilibrium was established. 
Following incubation, an aliquot of sample was removed 
for determination of the drug concentration post incu-
bation. Triplicate 500  μL aliquots of the samples were 
added to the sample reservoir of the UF unit with filtrate 
collection tubes. All ultrafiltration units were centrifuged 
at 13,000  rpm (15,000×g) for 15  min at 4  °C. Sample 
reservoirs containing the retentate were removed while 
25  μL of the filtrate from collection tubes were trans-
ferred to the 96 well plate format. Internal standard solu-
tion (500 μL) was added to each sample analyzed by the 
validated LC–MS/MS method described above. While 
non-specific binding to filtrate collection tubes and 
ultrafiltration apparatus were not formally studied via 
control samples, similar binding experiments were part 
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of the formal method validation and found to be negli-
gible. Hence, low recovery of the test compound was not 
anticipated.
Calculation of % of protein binding was as follows:
where Non Specific Binding (NSB) = 1 − (Cb,f/Cb,uf). Cb,f 
is the average concentration in the filtered PBS (ultrafil-
trate). Cb,uf is the average concentration in the unfiltered 
PBS (retentate). Cp,f is the concentration in the filtered 
matrix. C0 is the dosing concentration of the compound.
Statistical analysis
Data have been analyzed via basic descriptive statis-
tics with results from 3 to 5 independent experiments 
expressed as the mean ± SD in most cases as indicated 
in the figure legends. Evaluation of the significance of dif-
ferences between parameters of interest was performed 
using one-way ANOVA with post-test analysis by Bon-
ferroni’s Multiple Comparison Test or Student’s t test 
when appropriate.
Results
Effect of aprepitant on HIV infection in human MDM
Aprepitant inhibited HIV infection in MDM from both 
depressed and not depressed HIV negative individuals 
ex  vivo in a dose-dependent manner (Fig.  1a); p =  0.05 
aprepitant 1 μM versus control and p < 0.001 aprepitant 5 
and 10 μM versus control. A concentration of aprepitant 
of 10  μM is approximately equivalent to the IC90 value, 
and the IC50 value of aprepitant is about 5 μM. Depres-
sion status, sex, age or race had no effect on aprepitant 
inhibition of HIV infection in MDM (data not shown). 
Assay of aprepitant concentrations in culture media show 
little or no degradation during week long ex vivo, infec-
tivity experiments (Fig. 1b).
Aprepitant is highly protein bound
The protein binding study revealed that 99.9 % of aprepi-
tant is protein bound. Human plasma and FBS ultrafil-
tration protein binding results from three experiments 
consistently show similar (99.79–99.95  %) binding of 
aprepitant to human and rhesus macaque plasma and 
FBS. These results suggest that aprepitant is more potent 
than previously appreciated; free drug concentration 
(responsible for aprepitant’s activity) is substantially less 
that the total concentration used to estimate IC50 in the 
in  vitro experiments. Based on the free base aprepitant 
and converting to units of concentration based on aprep-
itant’s molecular weight yields a total IC50 concentration 
of 2.65  µg/mL. Correcting for protein binding yields a 
free drug IC50 concentration of ~2.65 ng/mL.





Aprepitant exposure and effect on SIV infection in rhesus 
macaque
Oral administration of aprepitant to non-human pri-
mates resulted in a dose dependent increase of aprepi-
tant concentrations in plasma and CSF. Mean aprepitant 
a
b
Fig. 1 Aprepitant inhibits HIV replication in MDM. a Monocytes 
were isolated from the blood samples from 125 depressed and not 
depressed HIV negative subjects (for detailed description of donor 
population see “HIV infection and depression: patients utilized for 
ex vivo analysis”). Following differentiation for 7 days MDM were 
infected with HIV Bal. Macrophages from each subject were exposed 
to all four experimental conditions as indicated (1, 5 and 10 μM 
concentrations of aprepitant). Control, HIV infected MDM were 
treated with aprepitant vehicle, 0.001 % DMSO. RNA was collected 
7 days after infection and assayed for expression of HIV GAG by real 
time RT PCR using the GAPDH housekeeping gene for normalization. 
GAG expression in control (non-treated) cultures were designated 
as 100 %; *p < 0.0001 between all groups including control were 
obtained through one-way ANOVA with post-test analysis by Bonfer-
roni’s Multiple Comparison Test indicating significant difference 
between all groups in pair wise comparison. b Aprepitant added to 
DMEM 10 % FBS media or MDM cultures at a concentration of 1 μM 
(0.53 μg/ml) on day 0 and measured on days 0, 1, 2, 3 and 7. Results 
are presented as mean ± SD for three independent experiments
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plasma concentrations on the dense sampling days (1, 7 
and 14) are shown in Fig. 2a. The distribution of steady-
state trough concentrations for the 80 and 125 mg once 
daily dose groups are shown in Fig. 2b. The mean steady-
state trough aprepitant concentrations in plasma were 0.6 
and 1.9  µg/mL respectively, suggesting slightly greater 
than proportional increases in exposure over this dose 
range. The ratio of CSF to plasma concentration ranged 
from 0.05 to 0.8 % consistent with the high degree of pro-
tein binding and independent of dose. Trough plasma 
concentration is essentially reach steady state by day 10 
in the rhesus while induction of CYP metabolism occurs 
by the second week of daily dosing. The extent of induc-
tion can be estimated by comparing the mean trough 
levels on days 13 and 14. The decline in trough exposure 
between these consecutive dosing days is approximately 
32.5  % which is similar to that observed in the ferret 
and rat [33–35]. There were no differences in systemic 
and neuropathology between aprepitant treated and 
untreated Rhesus macaques.
Based on the pilot study results yielding no side effects 
at a dose of 80  mg/day and sub-therapeutic exposure 
of aprepitant in plasma, we selected a dose of 125  mg/
day for the infectivity study in rhesus macaque. Treat-
ment of SIV infected rhesus macaques with aprepitant 
resulted in 1 log reduction in plasma levels of viral RNA 
as compared to non-treated controls (Fig.  3). Although 
reduction was not observed during acute infection (first 
3 month), it was clearly evident during the 3–12 month 
observation period. No side serious effects were associ-
ated with 125 mg dose during the yearlong study.
Monitoring of anxiety-related behavior for 20  weeks 
after infection demonstrated no significant difference 
between aprepitant treated and control groups during 
first 4 weeks after infection and significant reduction of 
anxiety thereafter (Fig. 4).
Anti‑inflammatory effect of aprepitant
Previously we reported that 2  weeks long daily admin-
istration of 375  mg of aprepitant to HIV positive indi-
viduals resulted in a decrease of serum levels of several 
pro-inflammatory cytokines, sCD163 and PD-1 expres-
sion on CD4 positive T-cells in  vivo [24]. To evaluate 
mechanism and specificity of anti-inflammatory aprepi-
tant action, PBMC from healthy donors were treated with 
SP in vitro with or without aprepitant present. Superna-
tants were analyzed using Multiplex inflammatory and 
immune response panel of cytokines and chemokines. 
SP upregulated production of the same cytokines and 
chemokines (G-CSF, IL-6, IL-8, TNFα and MIP-1α) 
which were down regulated by aprepitant in vivo (Fig. 5) 
[24]. In addition increased production of MCP-1 by SP 
was also detected. Aprepitant blocked the SP effect and 
DMSO had no effect. Incubation of PBMC with SP also 
resulted in increased PD-1 expression by CD4 T-cells 
(Fig.  6). The initial observation of increased percent of 
PD-1 positive CD4 T-cells was detected at day 4–5 (not 
shown) however a significant (p  =  0.03) increase was 
observed after 6–8  days of exposure to SP (day seven 
results are shown in Fig.  6). The SP effect was blocked 
by aprepitant. Exposure of human macrophages to SP 
resulted in fast release of sCD163 in a time- and dose-
dependent (p < 0.001) manner (Fig. 7) and this effect was 
also inhibited by aprepitant.
Discussion
Our paper address two provocative questions: the via-
bility of NK1R antagonism as a pathway for treating 
HIV-associated neurobehavioral and neurocognitive 
impairment and the suitability of aprepitant as a can-
didate molecule for this indication. We believe the data 
presented herein in addition to our and others’ previous 
findings support these contentions. This opinion, how-
ever, is counter to the common clinical belief which is 
heavily influenced by the use of aprepitant (Emend) for 
chemotherapy-induced nausea and vomiting (CINV) 
[36, 37] and failed clinical trials with aprepitant [38] and 
other NK1R antagonists in depression. However, this 
pathway may be clinically viable in depression at expo-
sures eliciting complete saturation of the NK1R receptor 
(100  % occupancy) [39, 40] and the bridge to neurobe-
havioral benefits may be tied to the immunomodulatory 
and anti-inflammatory effects achieved [2, 5, 17, 41]. The 
salient point for this class and aprepitant specifically is 
that multiple therapeutic windows may exist to support 
target exposures for CINV and HAND.
Specifically, the effects of aprepitant on HIV infection 
in MDM extend our previous findings on the involve-
ment of SP–NK1R signaling in HIV infection [8, 9, 19]. 
Using a large donor cohort we demonstrated inhibition 
of HIV infection in MDM ex vivo at a concentration of 
~5 µM from 125 depressed and non-depressed HIV neg-
ative individuals which is line with projected free drug 
trough concentrations [42] required to elicit 100 % NK1R 
occupancy. Based on both ultrafiltration and equilib-
rium dialysis experiments more than 99.9 % of aprepitant 
was determined to be protein-bound when exposed to 
human plasma or 10 % FBS. These values are somewhat 
higher than the previously reported >95  % binding [43, 
44] yielding free drug concentrations even lower than 
initially assumed. Likewise, the low CSF levels observed 
in monkeys confirm the low free fraction available to 
cross the blood brain barrier despite aprepitant’s lipo-
philicity. It should be noted that others have reported 
higher protein binding for aprepitant though not pub-
lished formal results. Specifically, it has been observed 
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and appreciated by regulatory authorities reviewing the 
original aprepitant submission [45]; these comments are 
likewise supportive of our results. The magnitude of the 
protein binding and the necessity of CNS penetration for 
both immunomodulatory and anti-inflammatory effects 
further supports the increased dosing requirements for 
aprepitant in HAND. Table 1 provides a broad overview 
of dosing requirements for similar agents across various 
therapeutic areas; in the majority of these agents daily 
dosing exceeded 600  mg/day. The only exceptions were 
Fig. 2 Aprepitant plasma and CSF concentrations in non-human primates. a Plasma aprepitant concentrations measured in rhesus monkeys 
(n = 3/group) following daily oral doses of 80 mg (square) or 125 mg (triangle). Data reflects mean aprepitant plasma concentrations on dense 
sampling days (1, 7 and 14) + SD. b Plasma (Cp) and CSF steady-state trough concentrations presented as box-n-whisker plots
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agents with high bioavailability (>90  %) and where the 
systemic circulation was the site of action. Observed 
aprepitant exposure following chronic administration is 
reduced due to CYP 3A4-mediated enzyme induction 
across species and was confirmed in our primate study as 
well. Human trials in HIV-infected patients [23, 24] have 
yet to demonstrate the magnitude of the induction effect 
because of the short dosing durations over which drug 
dosing occurred (2 weeks) while previous studies suggest 
that induction occurs at approximately the third week of 
dosing following the once daily regimen (Merck & Co, 
reference briefing document, FOI [45]).
Yearlong treatment of SIV infected Rhesus macaques 
with aprepitant resulted in approximately tenfold reduc-
tion of viral loads observed between weeks 12 and 52 
after infection. Coincidently, an anti-anxiolytic effect of 
aprepitant was observed during weeks 12 and 20 of ther-
apy. It is clear from these results that a significant reduc-
tion in the behavioral effects observed in SIV-infected 
animals is elicited over time with daily administration of 
aprepitant. The magnitude of this effect is comparable to 
that observed in previous pharmacology studies in rhesus 
macaque with other anti-anxiolytic agents [46, 47].
In human studies with a 2-week 375  mg daily regi-
men in HIV positive individuals, we observed a reduc-
tion in several pro-inflammatory markers associated 
with poor HIV prognosis including PD-1 expression on 
CD4 T-cells, plasma levels of SP, and sCD163. We dem-
onstrated a significant reduction in levels of G-CSF, 
MIP-1α, IL-6, IL-8 and TNFα after 2 weeks of aprepitant 
treatment [24]. These results are consistent with overall 
pro-inflammatory properties of SP [5, 6]. Reduction in 
plasma IL-6 levels is relevant since elevated IL-6 levels 
are linked to negative prognosis in chronic HIV [48]. In 
order to further evaluate these finding we measured SP 
and aprepitant effects in PBMC cultures from healthy 
HIV negative donors and found similar patterns of activa-
tion in vitro in comparison to human studies [24]. Treat-
ment with SP increased production of the same cytokines 
and sCD163 with the exception of MCP-1 which changes 
were not observed in  vivo, and increased frequency of 
PD-1 positive CD4 T-cells in  vitro. SP effects in  vitro 
were blocked by aprepitant. Chronic inflammation 
associated with HIV infection is also a likely cause of 
increased PD-1 expression and elevated plasma sCD163 
levels in  vivo. In this context it is not surprising that a 
compound with anti-inflammatory properties such as 
aprepitant reduces levels of those markers both in  vivo 
and in vitro. Likewise, aprepitant’s composite effect also 
supports a role in the restoration of NK and T-cell func-
tions, a potential therapeutic benefit in the treatment of 
chronic HIV.
While ex  vivo experiments, non-human primate and 
human clinical studies indicate that NK1R antagonists 
may have limited use as monotherapy in HIV, they may 
be beneficial when used in combination with anti-ret-
rovirals in chronic HIV given their anti-inflammatory 
effects and potential to improve neurocognitive functions 
through possible reduction in symptoms of depression 
and anxiety as well as improved sleep [40]. Defining the 
therapeutic dose of aprepitant in HIV requires a more 
definitive assessment of the target population and indi-
cation (HAND and/or related subgroups) as well as the 
potential comorbidities in these patients. In any case the 
dose is likely to be substantially higher than the 165 mg 
Fig. 3 Plasma viral load in rhesus macaque* receiving 125 mg/day 
aprepitant * eight male rhesus macaques (Macaca mulatta) were 
infected with SIVmac251. Treated animals (n = 4/group) were admin-
istered 125 mg of aprepitant daily by the oral route, starting at day 0 
for the duration of the study. Results are presented as mean ± SD for 
each group of animals
Fig. 4 Anxiety-related behavior* time course in SIV infected rhesus 
macaque receiving aprepitant at 125 mg/day or placebo. *Anxiety-
related behavior was calculated based on the following parameters: 
body shake, hypervigilant scanning, self-licking and self-grooming, 
scratching, unresponsive inactivity and yawning. Results are pre-
sented as mean ± SD for each group of animals (n = 4/group)
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dose of aprepitant reported to achieve 97–99 % receptor 
occupancy in PET studies [7, 43]. The case for indication-
specific dosing of NK1R antagonists has been previously 
discussed [39, 40], e.g., while partial receptor occupancy 
was sufficient to see improvement in insomnia, nearly 
100  % occupancy may be required to see an effect in 
major depression [39], though a mechanistic rationale for 
these windows is still absent.
Other drugs and/or drug classes elicit multiple target 
exposure thresholds based on different clinical disease 
manifestations. This is the case for methotrexate, mino-
cycline, thalidomide, prednisone and minoxidil and likely 
Fig. 5 SP dependent up regulation of cytokine and chemokine production by human PBMC* is inhibited by aprepitant. *Freshly isolated PBMC 
from normal donors were incubated for 24 h with SP and/or Aprepitant (10 µM each) as indicated. Control cultures were either left untreated 
of incubated with DMSO (vehicle for aprepitant). Pro-inflammatory markers were measured in supernatants using MILLIPORE Human Cytokine/
Chemokine Magnetic Bead Panel. Results are presented as mean ± SD for three independent experiments. *Statistically significant difference from 
control (p < 0.05)































Fig. 6 Aprepitant blocks SP induced PD-1 expression on CD4+ T-cells. PBMC were treated for 7 days with SP and aprepitant as indicated. PD-1 
expression was measured by flow cytometry on CD3+CD4+ cells and expressed as percentage of PD-1 positive cells. a Results from representa-
tive experiment are shown. First two columns show gaiting strategy. Last column shows percent of PD-1 positive CD4 cells. b Mean results from five 
independent experiments and SD are shown; p values determined by paired Student’s t test. Median (spread): control 14.7 (11.1), SP treated 38.4 
(60.6), SP + aprepitant treated 7.8 (6.0)
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other well-known medicines. Likewise, these drugs have 
different dosing requirements for the various indications 
they seek to treat and, in many cases, there are well-
designed clinical trials that support their registration in 
these indications as well as the specific dosing guidance. 
While we may have clearly defined mechanisms that sup-
port the separate disease targets (e.g., methotrexate for 
osteosarcoma vs. rheumatoid arthritis), in many cases 
exact pathways are less well understood. Interestingly, in 
the HIV arena, the drug efavirenz is only recently being 
appreciated for its multimodal actions despite its primary 
indication as part of the current HART standard of care. 
Specifically, efavirenz has been found to act as a 5-HT2A 
receptor partial agonist (Ki  =  2.2  μM), 5-HT2C recep-
tor ligand, serotonin and dopamine reuptake inhibitor 
(50 and 75  % inhibition at 10  μM, respectively), vesicu-
lar monoamine transporter 2 (VMAT2) inhibitor (60  % 
inhibition at 10  μM), and positive allosteric modulator 
of the GABAA receptor [49, 50]. It is generally believed 
that these properties, especially actions at 5-HT2 recep-
tors, are involved in its neuropsychiatric adverse effects 
(depression, anxiety, hallucinations, aggression, suicidal 
ideation, and sleep disturbance), as they are alleviated by 
cyproheptadine, a drug with 5-HT2 receptor antagonist 
actions [49, 50].
Pro-inflammatory effects are a major contributor to 
co-morbidities in HIV. Our observed reduction in pro-
inflammatory biomarkers (IL-6, IL-8, TNFα, sCD163, 
PD-1) provides evidence that potential synergy with 
cART may be attained via NK1R blockade. Any down-
stream effects with aprepitant would be expected to 
result in improved clinical consequences in both mor-
bidity and mortality. Similar agents may be attractive 
for adjuvant therapy in neuro AIDS as well. Studies to 
evaluate the anti-inflammatory effects of aprepitant with 
longer treatment (4  weeks) and co-administration with 
ritonavir (CYP 3A4 inhibitor) to boost aprepitant plasma 
concentrations in virologically suppressed patients on 
cART are ongoing (Clinical Trials.gov # NCT02154360) 
but additional long-term trials will be essential to con-
firm proof-of-concept based on these promising support-
ive investigations.
Conclusions
Our results provide evidence of a unique combination of 
antiretroviral, anti-inflammatory and behavioral modula-
tion properties of aprepitant in  vitro and in  vivo. These 
results also provide robust support for a clinical expo-
sure target above that recommended for chemotherapy-
induced nausea and vomiting. Doses up to 375 mg once 
daily in HIV-infected patients still elicit sub-therapeutic 
exposure of aprepitant though effective plasma concen-
trations are likely achievable via proper dose. Proper 
modulation of the aprepitant dose will be an important 
factor in the overall success of this mechanism especially 
given the heterogeneity of the target population and the 
polypharmacy that defines the current standard of care.
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Fig. 7 SP induces cleavage of CD163 in monocytes. sCD163 was 
measured by ELISA in the supernatant of freshly isolated human 
monocytes treated with SP and aprepitant as indicated. a Time 
course of cells treated with varying doses of SP as indicated. 
*p < 0.001 control versus 5 and 10 μM of SP. b Cells were pre-incu-
bated with aprepitant (10 μM) for 30 min and then treated with SP 
(5 μM) for 60 min. *p < 0.001 SP versus control, p = 0.004 SP versus 
SP + aprepitant. Results are presented as mean ± SD from three 
independent experiments
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